Breaking News Bar

Business News and Information

FDA rejects Alkermes' depression drug, questions effectiveness

The FDA has rejected Alkermes' depression drug, echoing past questions around the drug's effectiveness and the data the company presented. The company's stock price fell 4 percent in after-hours trading and has fallen 19 percent since last fall.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear